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Abstract 
It has been proposed previously that the sustained activation of mitogen-activated protein kinase may be necessary for the differentiation of PC12 
cells. Differentiation of PC12 cells is induced by many extracellular agonists including nerve growth factor (NGF) and cyclicAMP analogues, but 
not epidennal growth factor (EGF), insulin or phorbol esters. Our results demonstrate that: (i) 8-(4-chlorophenylthio)-cyclicAMP (CPT-CAMP) 
activates MAP kinase; this raises the possibility that the MAP kinase pathway may be activated by agents that act through adenylate cyclase; (ii) 
NGF and UT-CAMP as well as phorbol esters promote sustained activation of MAP kinase. This suggests that while sustained MAP kinase activation 
may be associated with differentiation it may not be sufficient, and that other as yet unidentified parallel pathways may be involved. 
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1. Introduction 
The mitogen-activated protein (MAP) kinases are 
stimulated by a wide variety of extracellular agents in- 
cluding growth factors (e.g. EGF and PDGF), neurotro- 
phins (e.g. NGF), insulin and phorbol esters (reviewed 
in [l-3]). The pathways by which these enzymes (includ- 
ing ERKl and ERK2) are activated have become in- 
creasingly well characterised in the past few years. Sev- 
eral MAP kinase kinases have now been identified that 
can phosphorylate and activate the MAP kinases (see [3] 
for recent review) and at least three MAP kinase kinase 
kinases have been identified that phosphorylate and acti- 
vate MAP kinase kinases e.g. Rafl [4-61, Mos [7] and 
MEKK [8]. Recently, several groups have demonstrated 
that Rafl associates with Ras [9-121 but i is not known 
how this simple association could lead to Rafl activa- 
tion. 
Growth factors, insulin and neurotrophins promote 
widely differing cellular responses, and thus it remains 
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to be firmly established how the MAP kinase cascade 
could play a central role in the actions of this diverse 
array of extracellular agonists. A good example is the rat 
phaeochromocytoma (PC12) cell line in which NGF, but 
not EGF, insulin or phorbol esters, promotes differenti- 
ation into a cell type resembling sympathetic neurones 
[13,14]. 
Although both NGF and EGF promote a rapid acti- 
vation of MAP kinase in PC12 cells, the activation in 
response to EGF is transient while that in response to 
NGF is sustained over a period of several hours and this 
is accompanied by parallel changes in MAP kinase ki- 
nase activation [15-171. Furthermore, NGF, but not 
EGF, was reported to promote the translocation of 
MAP kinase immunoreactivity into the nucleus [16,17]. 
It was proposed on the basis of these results that a sus- 
tained activation of the MAP kinase cascade might be 
required for the differentiation of PC12 cells [15,16]. If 
such a phenomenon is central to the differentiation re- 
sponse then it should also apply to other agents which 
promote PC12 cell differentiation, including CAMP ana- 
logues such as dibutyryl cyclicAMP [18], interleukin 6 
[19] and fibroblast growth factors [l&20]. As CAMP is 
well known to activate the CAMP-dependent protein ki- 
nase and had not previously been reported to regulate 
the activity of MAP kinase, we examined whether a more 
membrane permeant CAMP analogue, S-(4-chlorophen- 
ylthio)-cyclicAMP (CPT-CAMP) would promote PC12 
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cell differentiation and concomitant activation of MAP 
kinase. In addition we investigated the time course of 
activation of MAP kinase by insulin and PMA, agents 
which do not promote PC12 cell differentiation. 
2. Materials and methods 
2. I. Materials 
All reagents were as previously described [21] except tissue culture 
media and serum which were from Gibco BRL (Paislev, UK). and 
8(4-chlorophenylthio)-cyclicAMP which was from Sigma (Poole; UK). 
An antiserum (pan-ERKlR) reactive towards both ERKl and ERK2 
was raised essentially as described by Boulton and Cobb [22] towards 
the peptide CAIFQETARFQPGAPEAP (corresponding to the C-ter- 
minal 15 amino acids of ERKl) coupled to keyhole limpet haemocy- 
anin. For Western blot analysis the serum was affinity purified by 
chromatography on a Sepharose column containing covalently coupled 
ERKl C-terminal peptide; bound antibodies were eluted with 0.2 M 
glycine (pH 2.5) followed by extensive dialysis against phosphate buff- 
ered saline. PC12 cells were maintained in collagen coated plates with 
DMEM medium supplemented with 10% foetal calf serum and 5% 
horse serum. 
2.2. Assay of MAP kinase in anti-ERK immunoprecipitates 
Approximately 2 x lo6 cells in 60-mm dishes were serum starved by 
incubation at 37°C for 120 min in 2 ml of serum-free medium. After 
incubation with ligands for the times and at the concentrations indi- 
cated in the figure legends, the cells were washed with 2 ml of ice-cold 
phosphate-buffered saline and rapidly extracted by scraping into 0.5 ml 
of ice-cold extraction buffer (50 mM /3glycerophosphate (pH 7.4), 1.5 
mM EGTA, 1 mM benzamidine, 1mM dithiothreitol, 0.5 mM Na,VO,, 
0.1 mM PMSF, 1 PM microcystin, 1 @ml each of pepstatin, antipain 
and leupeptin). After centrifugation at 10,000 x g for 15 min at 4°C the 
supematants were incubated with 5 ~1 of pan-ERK112 antiserum and 
2.5 mg protein A-Sepharose (Sigma, Poole, UK) by tumbling for 2 h 
at 4°C. The beads were washed three times with extraction buffer 
without microcystin and resuspended in 50 ~1 extraction buffer. Pellets 
(20 ~1) were assayed in duplicate incubations (50 ~1 final volume) 
containing 20 mM MOPS (pH 7.4), 3 mM EGTA, 10 mM MgCl,, 1 PM 
microcystin, 1 PM-CAMP-dependent protein kinase inhibitor peptide 
and 0.5 mg/ml myelin basic protein. Reactions were initiated by the 
addition of [Y-~~P]ATP (50 PM; - 500 cpm/pmol) and after 15 min at 
30°C terminated by spotting a 30 ~1 sample onto P8 1 phosphocellulose 
paper squares. Papers were washed four times with 150 mM H,PO, and 
counted in 10 ml of water by the Cerenkov method. 
2.3. Western blot analysis 
A PC12 cell lysate (500 ml) was prepared as described above and 
solubilized by addition of 100 ~1 of SDS sample buffer. Proteins were 
separated on a 7% polacrylamide gel, transfered to Immobilon P mem- 
brane (Millipore Corporation, Bedford, USA) and Western blotted 
with affinity-purified pan-ERKl/2 (75 &ml) followed by chemilu- 
minescent detection as described [23]. 
2.4. Fractionation of PC12 extracts by MonoQ FPLC 
Cell extracts (approx. 3 mg of protein) prepared as described above 
were loaded onto a MonoQ HR S/5 column (Pharmacia) at a flow rate 
of 0.5 ml/min, pre-equilibrated with buffer A (50 mM B-glycero- 
phosphate (pH 7.4), 1 mM EGTA, 1 mM dithiothreitol). The column 
flow-through was collected and the column washed with buffer A until 
the absorbance at 280 nm returned to baseline. The column was devel- 
oped, at a flow rate of 0.5 ml/min, with a linear gradient o 0.5 M NaCl 
in buffer A. Fractions (0.5 ml) were collected into tubes containing 50 
ml of 50 mM /?-glycerophosphate (pH 7.4), 2 mM Na9V0,. Fractions 
(20~1) were assayed for MAP kinase activity using myelin basic protein 
as a substrate as described above except that the reactions were per- 
formed in 96-well microtitre plates. Reactions were terminated with 20 
~12 M HCl and applied to an 8 cm x 12 cm P8 1 paper square using an 
8 x 12 Hybridot manifold (BRL, Cambridge, UK). The P81 paper was 
then washed four times with 500 ml 150 mM H,PQ,, dried and 32P- 
incorporation determined using a PhophorImager (Molecular Dynam- 
its, USA). Standard samples of known amounts of [r-32P]ATP were 
included to allow conversion of spot intensity to cpm. This method 
allowed the rapid and sensitive assay of several hundred samples with 
relative ease, and gave results which were essentially identical to those 
obtained using the standard assay method described previously. 
3. Results and discussion 
We first assessed the ability of the 8-(4-chlorophenyl- 
thio) analogue of CAMP to induce neurite outgrowth in 
PC12 cells. As shown in Fig. 1, after 24 h treatment, 
CPT-CAMP promoted neurite outgrowth in PC12 cells 
to an extent which was almost indistiguishable to that 
induced by NGF. Identical results were observed in 
serum starved cells (data not shown). This confirms, 
therefore, the observations of Togari et al. [18] who used 
the less permeant dibutyryl analogue of CAMP. In addi- 
tion, we confirmed that EGF (100 nM), insulin (100 nM) 
and PMA (1.6pM) did not induce any detectable neurite 
outgrowth in these cells (data not shown). These concen- 
trations of agents were chosen to give maximal levels of 
response for each agonist. 
PC12 cells were then treated with various agents and 
extracted in the presence of protease and phosphatase 
inhibitors. MAP kinase was immunoprecipitated from 
these cell extracts using a pan-ERKl/2 antiserum, and 
the activity in the immunoprecipitates assayed using my- 
elin basic protein as substrate. This serum is highly spe- 
cific for the ERKl and ERK2 isoforms of MAP kinase 
as determined by Western blot analysis of PC12 cell 
lysates (Fig. 2b). 
Fig. 1. Induction of neurite outgrowth in PC12 cells treated with NGF 
and CPTcAMP. PC12 cells in collagen coated dishes were treated 
without (a) or with 50 &ml NGF for 24 h (b) or with 0.5 mM CPT- 
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Fig. 2. Time course of activation of MAP kinase in PC12 cells PC12 
cells were incubated for the indicated times with (a) agents hat promote 
neurite outgrowth such as 50 @ml NGF (m) or 0.5 mM CPT-CAMP 
(A) and (b) with agents that do not promote neurite outgrowth such 
as 1.6 PM PMA (w), 100 nM EGF (A) or 100 nM insulin (0). Cell 
extracts were prepared and MAP kinase immunoprecipitated with pan- 
ERKlR antiserum and assayed for its ability to phosphorylate myelin 
basic protein as described in section 2. Each data point represents the 
mean f S.E.M. of at least three separate observations. Panel b, inset: 
PC12 cell lysate was Western blotted with affinity purified pan-ERKl12 
antiserum followed by ECL detection as described in section 2. The 
apparent molecular weights of the isoforms in our hands are 44 kDa 
(open triangle) and 51 kDa (closed triangle) (see also Dickens et al. 
Pll). 
We first examined the ability of two agents that pro- 
mote neurite outgrowth to activate MAP kinase, namely 
NGF and CPT-CAMP. Both promoted a sustained acti- 
vation of MAP kinase (Fig. 2a). The NGF response was 
consistently biphasic with activation peaking at 10 min, 
dropping slightly over the next 20 min and followed by 
a small slower rise such that the activity at 60 min was 
approx. 40-fold above basal (Fig. 2a; it should be noted 
that it is difficult to quantitate accurately the extent of 
activation as the basal activities observed using our assay 
method were very low). CPT-CAMP promoted a consis- 
tently more rapid rise in MAP kinase activity which 
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peaked at 5 min (apparently -lOO-fold over basal) and fell 
only slowly over the next hour (Fig. 2a). 
We next examined the time course of activation of 
MAP kinase by agents that do not promote neurite out- 
growth but which, nevertheless, are well known MAP 
kinase activators. As expected, EGF induced a transient 
activation of MAP kinase (maximal at 5 min; Fig. 2b). 
Insulin also promoted a transient activation of MAP 
kinase although the extent of activation, while still - 9-fold 
above basal at 10 min, was considerably lower than that 
induced by EGF (Fig. 2b). In several experiments we 
have been unable to demonstrate neurite outgrowth in 
our PC12 cells in response to FGF (in contrast with 
Togari et al. [18] and Rydel and Greene [20]). The cells 
do, however, respond to FGF as we see a small and 
transient activation of MAP kinase rather similar to that 
observed with insulin (S.W.Y., unpublished observa- 
tions). 
Thus far the data is clearly consistent with the hypoth- 
esis that only a sustained activation of MAP kinase is 
associated with neurite outgrowth in PC12 cells (see in- 
troduction). Surprisingly, therefore, we found that phor- 
bol esters, which do not promote neurite outgrowth, also 
promoted a sustained activation of MAP kinase 
20 25 30 35 40 
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Fig. 3. MonoQ separation of MAP kinases after activation by NGF, 
PMA or CPT-CAMP. PC12 cells were incubated in the absence (a) or 
presence of 50 ng/ml NGF for 10 min (b), 0.5 mM CPT-CAMP for 10 
min (c), 1.6 PM PMA for 10 min (d) or 1.6 PM PMA for 120 min (e). 
Subsequently prepared extracts (equal amounts of proteins) were sepa- 
rated by MonoQ FPLC and fractions assayed for myelin basic protein 
kinase activity as described in section 2. 
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(Fig. 2b). The initial magnitude of the PMA effect was 
generally greater than that of NGF, peaking at 10 min 
and falling back to a level at 60 min which was not 
significantly different to that observed with either NGF 
or CPT-CAMP (compare Fig. 2b with 2a). The activation 
of MAP kinase in response to phorbol esters and NGF 
remained elevated for at least a further two hours (data 
not shown). 
We obtained very similar results to those illustrated in 
Fig. 2 when we performed assays either in immunopre- 
cipitates using a distinct antiserum, A249 (specific for 
ERK2; a gift from Dr M.H. Cobb, Department of Phar- 
macology, Southwestern Medical Center, Dallas) or in 
crude cell lysates (data not shown). 
We further confirmed that the myelin basic protein 
kinase activities seen in the pan-ERKl/2 immunoprecip- 
itates were indeed MAP kinase by separating cell extracts 
by MonoQ chromatography (Fig. 3). Two peaks of my- 
elin basic protein kinase activity were observed after 10 
min treatment with NGF and CPT-CAMP. These were 
confirmed as ERK2 and ERKl (eluting in fractions 26 
and 28, respectively), by Western blotting with antisera 
specific for these isoforms (S.W.Y., M.D. and J.M.T., 
unpublished observations). Interestingly, ERK2 was the 
predominant MAP kinase isoform activated in response 
to PMA after 10 min, while ERKI was stimulated more 
slowly, only becoming significantly activated at 120 min 
(Fig. 3). Clearly the mechanism of this differential activa- 
tion of ERKI and ERK2 by phorbol esters is of further 
interest. 
Phorbol esters do not promote neurite outgrowth, thus 
the sustained activation of MAP kinase, while possibly 
necessary, is not sufficient for neurite outgrowth in PC12 
cells. Perhaps NGF and CPT-CAMP, but not PMA, acti- 
vate other parallel pathways that are required for the 
differentiation response. However, we cannot rule out 
the possibility that PMA (but not NGF or CPT-CAMP) 
causes the down-regulation of a component(s) of the 
differentiation machinery, although this is rather un- 
likely as phorbol esters do not block NGF-induced 
neurite outgrowth [ 131. 
Others have demonstrated that MAP kinases translo- 
cate to the nucleus in reponse to NGF but not EGF 
[ 16,171. Despite the fact that our pan-ERKl/2 antiserum 
demonstrates considerable immunoreactivity with cy- 
tosolic and nuclear ERKl and ERK2 by Western blot- 
ting of subcellular fractions and by immunofluorescence 
confocal microscopy, we have been unable to detect any 
effect on translocation upon treatment of PC12 cells with 
any agonist. The reasons for this are not known and thus 
we have been unable to investigate the effect of CPT- 
CAMP or PMA on MAP kinase translocation. 
The effect of CPT-CAMP is clearly of considerable 
interest. There are several reports that in some cell types 
CAMP antagonises growth factor-activated MAP kinase 
[24-261. By contrast, in dog thyroid epithelial cells, MAP 
kinase is unaffected by CAMP [27]. The interaction be- 
tween the MAP kinase pathway and the CAMP-depend- 
ent protein kinase pathway must depend, therefore, on 
the cell type involved and thus the mechanisms involved 
are likely to be complex. 
How may CPT-CAMP activate MAP kinase in PC12 
cells? The ability of CPT-CAMP to activate other mem- 
bers of the MAP kinase cascade (e.g. Rafl and MAP 
kinase kinase) now warrants investigation. Perhaps 
CPT-CAMP activates the recently identified MEKK, the 
murine homologue of Saccharomyces cerevisiae Stel I, 
which phosphorylates and activates MAP kinase kinase, 
and has been shown to be expressed in PC12 cells [S]. In 
Saccharomyces cerevisiae, Stell is activated via a G- 
protein-dependent pathway from the ‘serpentine recep- 
tors’ and this has lead Lange-Carter et al. [8] to propose 
that MEKK might play a similar role in mammalian cells 
(see also Gardner et al. [28]). Alternatively perhaps, by 
promoting inhibitor- 1 phosphorylation and thus inhibi- 
tion of protein phosphatase-I activity [29], the dephos- 
phorylation and thus activation of Rafl or MAP kinase 
kinase could be achieved. This would be unlikely as a 
mechanism of direct regulation of MAP kinase itself as 
one would have to invoke parallel increases in Thr-183 
and Tyr-185 phosphorylation to achieve activation [I]. 
This possibility awaits identification of the physiologi- 
cally relevant phosphatases involved in the regulation of 
the MAP kinase pathway. 
In conclusion, therefore, we have shown that MAP 
kinase can be activated by a CAMP analogue through a 
mechanism that remains to be established. This activa- 
tion is sustained and associated with neurite outgrowth. 
However, our data demonstrate that while sustained 
MAP kinase activation is associated with, it may not be 
sufficient for, neurite outgrowth and that other as yet 
unidentified parallel pathways may be involved. 
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